AlphAIAlphAI — Financial news for AI agents
yahoo.comSEP 202 min read$AXSM

Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference

Axsome Therapeutics (NASDAQ:AXSM) presented at the H.C. Wainwright Conference, highlighting growth for Auvelity, with estimated peak sales of over $8 billion. Sunosi and SYMBRAVO also showed potential, with peak sales estimates of $300M-$500M and $500M-$1B, respectively. The company has multiple pipeline milestones and expects annual NDA filings through 2031. Axsome reported $320M in cash and expects profitability soon.

Original reporting
yahoo.com
Published Sep 20, 2026, 10:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 20, 2026, 11:11 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference — source image
Source · yahoo.com
Decision brief

The 30-second read

$AXSMBullishMed
01

Why it matters

The disclosed financials and pipeline milestones constitute the first public release of this data, offering new insight into the company's growth trajectory.

02

Market read

Guidance and pipeline news may influence Axsome's stock and peers in the CNS therapeutic space.

03

What to watch

Potential regulatory delays and reimbursement challenges for new indications.

Relevance 7/10Novelty 7/10Timing: conference today

Background

Axsome presented at the H.C. Wainwright conference, providing updates on Auvelity sales, Sunosi, SYMBRAVO, and pipeline candidates.

Company-level read

Ticker impact

$AXSMBullishHigh confidence
Context

Axsome Therapeutics disclosed Q2 revenue of $750M for Auvelity and $320M cash balance, plus pipeline updates and peak‑sales potential estimates.

Expected impact

Potential modest price appreciation if market digests growth outlook.

Evidence & confidence

First‑report of fresh sales figures and pipeline milestones provides new material for valuation.

Market effects

Sector

Highlights growth potential in CNS therapeutics, may lift peer sentiment.

Regional

U.S. biotech sector sees incremental bullish pressure.

Global

Limited to investors focused on CNS drug pipelines.

Counterpoint

What could challenge this read

Execution risk and competitive pressures could temper upside despite strong cash.

Key entities

  • company
    Axsome Therapeutics

    Biopharma focused on CNS disorders.

Read at source← All news

Related articles

SEP 12
$AXSMMedAI 8/10

Should First Patient Dosed Require Action From Axsome Therapeutics Stock Investors?

Axsome Therapeutics (AXSM) dosed the first patient in a Phase 3 trial (SUMMIT) for AXS-05 in smoking cessation. The trial compares AXS-05 to bupropion and placebo, with abstinence at week 12 as the primary endpoint. Success could expand AXS-05's use and leverage its patent estate until 2043. Analysts project $2.5B revenue and $908.3M earnings by 2029, but risks include cash burn and trial execution.

simplywall.st3 min
SEP 6
$AXSMMedAI 8/10

The Bull Case For Axsome Therapeutics (AXSM) Could Change Following AXS-05 Phase 3 Smoking Trial Launch

Axsome Therapeutics (AXSM) has initiated a Phase 3 trial for AXS-05 in smoking cessation, aiming to expand its use beyond existing approvals. The trial's success could enhance the company's long-term outlook, though near-term focus remains on commercializing Auvelity, Sunosi, and SYMBRAVO. Analysts project varying revenue and earnings forecasts for 2029, with some seeing significant upside.

simplywall.st3 min
AUG 31
$AXSMMedAI 8/10

Axsome doses first patient in phase 3 smoking cessation trial

Axsome Therapeutics (AXSM) dosed the first patient in its Phase 3 SUMMIT trial for AXS-05 as a smoking cessation treatment. The study will assess efficacy and safety over 12 weeks. AXS-05 is approved for other uses but not yet for smoking cessation. The company holds patents for the drug until at least 2043. Smoking affects 34 million adults in the U.S., costing over $300 billion annually.

investing.com2 min